)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shanghai Pharmaceuticals
Shanghai Pharmaceuticals (601607) investor relations material
Shanghai Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
9M 2026 revenue rose 3.67% YoY to RMB 222.96bn; net profit attributable to shareholders fell 10.90% to RMB 4.59bn, while adjusted net profit rose 25.02%.
Operating cash flow increased 127.54% YoY to RMB 5.35bn, supported by higher cash receipts from sales and services.
Financial highlights
Q3 revenue was RMB 75.49bn, up 2.74% YoY; attributable net profit was RMB 1.08bn, up 57.15%, and adjusted attributable profit was RMB 897m, up 49.69%.
9M total profit was RMB 7.56bn, down 8.94% YoY; net profit was RMB 5.77bn versus RMB 5.99bn a year earlier.
9M non-recurring gains totaled RMB 1.21bn, including RMB 1.19bn from disposal of non-current assets; adjusted attributable net profit was RMB 3.37bn.
Total assets reached RMB 242.05bn at Sep. 30, up 3.82% from year-end 2025; attributable equity rose 4.55% to RMB 79.34bn.
Outlook and guidance
Strategy prioritizes innovation-drug lifecycle services, CSO and SPD offerings, medical-device and health services, new retail, and digital transformation to support continued growth.
Plans include building an integrated specialist-pharmacy network and expanding innovation partnerships across the pharmaceutical supply chain and payment ecosystem.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shanghai Pharmaceuticals
- Revenue up 4.15% to RMB 147.47B; net profit down 21.40% on one-offs, adjusted profit up 1.65%.601607
H1 2026 - Revenue and net profit rose over 6% year-over-year, driven by strong segment growth.601607Q1 2026
- Net profit surged 25.74% on one-time gains, while adjusted profit declined 5.56% year-over-year.601607H2 2025
- Q3 profit dropped 38% on higher impairments, but YTD revenue and net profit rose on one-time gains.601607Q3 2025
- Revenue up slightly, but net profit declined amid cost pressures; innovation segments strong.601607Q1 2025
- Net profit surged 51.56% on a 1.56% revenue increase, driven by a one-time consolidation gain.601607H1 2025
- Revenue and net profit rose, driven by commercial and CSO sales despite industrial decline.601607Q3 2024
- H1 2024 revenue up 5.14%, net profit up 12.72%, interim dividend proposed.601607H1 2024
- Net profit surged 20.82% on 5.75% revenue growth, with strong cash flow and R&D investment.601607H2 2024
Next Shanghai Pharmaceuticals earnings date
H2 202626 Mar, 2027
Shanghai Pharmaceuticals
Next Shanghai Pharmaceuticals earnings date
H2 202626 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Shanghai Pharmaceuticals Holding is a healthcare company engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across multiple segments, including prescription drugs, over-the-counter medications, and healthcare services. Additionally, it provides supply chain solutions and distribution services to hospitals, pharmacies, and other healthcare providers. The company is headquartered in Shanghai, China, and its shares are listed on the Shanghai Stock Exchange (SSE).